More than 37,000 Americans diagnosed with pancreatic cancer this year, and 75 % die within the first 12 months after diagnosis. Pancreatic cancer is the fourth leading cause of cancer death in the United States, nor any of the under-funded for research.
PanCAN works to focus national attention on the need to find a cure for pancreatic cancer. We offer public and professional education embracing the urgent need for more research, effective treatments, prevention programs and early detection methods. PanCAN also funds research grants for pancreatic cancer, as well as providing community services. Volunteers across the country to help us to achieve our goals.. About PanCANthe pancreatic Cancer Action Network , established in 1999, is the first national patient organizations for the pancreatic cancer community organization.In July 2009 – NICE is recommended rituximab as an option on first-line operation in combination with FC chemotherapy.. Cancer of the blood MabThera for a wider application in patients with the most frequent chronic Leukaemia.
– refractory to fludarabine or were previously treated with rituximab – About CLLCLL is a blood cancer malfunction of a malfunction of a certain type of white blood cells . Healthy B-cells part in the control of infectious by production of antibodies. B cells, normally be usually in a controlled reproduce means that to normal function of CLL cells is impaired and the B-cells eventually damaged out of control.